Related Experiment Video
Updated: Jun 3, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Paediatric antiretroviral drug targets
Amy Slogrove1, Helena Rabie, Mark Cotton
1Department of Pediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa. amy@sun.ac.za
Infectious Disorders Drug Targets
|March 17, 2011
Summary
Early antiretroviral therapy benefits children with HIV-1. New drug classes and formulations are crucial for improving treatment outcomes and reducing vertical transmission in pediatric populations.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
Background:
- HIV-1 infection poses significant challenges for children, particularly in lower-income countries.
- While early antiretroviral (ARV) therapy is beneficial, there's a lack of pharmacokinetic data for established ARV classes in infants and children.
- Practical challenges exist in administering ARV medications to pediatric patients.
Purpose of the Study:
- To review current ARV treatment regimens in light of new vertical transmission prevention guidelines.
- To discuss the impact of physiological changes on pharmacokinetics in infants and children.
- To present new and developing ARV drug classes and novel drug delivery systems for pediatric use.
Main Methods:
- Discussion of current treatment challenges and new guidelines.
- Review of physiological changes affecting pediatric pharmacokinetics.
- Presentation of established and novel ARV drug classes, including entry inhibitors, integrase inhibitors, and others.
- Review of relevant pediatric studies and novel drug delivery systems.
Main Results:
- New ARV drug classes offer alternative options for treatment-experienced patients.
- Novel drug delivery systems show potential for enhanced adherence, improved drug exposure, and reduced side-effects.
- Emerging drug classes and delivery systems may further reduce vertical HIV transmission and improve neurological outcomes.
Conclusions:
- Optimizing ARV therapy in children requires better pharmacokinetic data and child-friendly formulations.
- New drug classes provide options for multi-drug resistant HIV and disease modification.
- Advancements in novel drug classes and delivery systems hold promise for reducing vertical HIV transmission and improving pediatric health outcomes.
More Related Videos
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...